Table 2:
Frequently Used Concomitant Medications
| Bexagliflozin 20 mg (N=157), n (%) |
Placebo (N=155), n (%) |
Total (N=312), n (%) |
|
|---|---|---|---|
|
| |||
| Any Concomitant Medication | 157 (100) | 154 (99.4) | 311 (99.7) |
| Drugs Used in Diabetes | 149 (94.9) | 149 (96.1) | 298 (95.5) |
| Insulin | 89 (56.7) | 91 (58.7) | 180 (57.7) |
| Non-Insulin | 125 (79.6) | 126 (81.3) | 251 (80.4) |
| Alpha Glucosidase Inhibitors | 8 (5.1) | 2 (1.3) | 10 (3.2) |
| Biguanides | 57 (36.3) | 73 (47.1) | 130 (41.7) |
| Dipeptidyl Peptidase 4 Inhibitors | 71 (45.2) | 61 (39.4) | 132 (42.3) |
| Glucagon-like Peptide-1 Receptor Agonists | 17 (10.8) | 13 (8.4) | 30 (9.6) |
| Meglitinides | 12 (7.6) | 12 (7.7) | 24 (7.7) |
| Sulfonylureas | 35 (22.3) | 37 (23.9) | 73 (23.1) |
| Thiazolidinediones | 13 (8.3) | 10 (6.5) | 23 (7.4) |
| Combination Oral Agents | 6 (3.8) | 6 (3.9) | 12 (3.8) |
| Lipid Modifying Agents | 133 (84.7) | 120 (77.4) | 253 (81.1) |
| Agents Acting on the Renin-Angiotensin System | 113 (72.0) | 117 (75.5) | 230 (73.7) |
| Antithrombotic Agents | 93 (59.2) | 102 (65.8) | 195 (62.5) |
| Drugs for Gastric Acid Related Disorders | 66 (42.0) | 75 (48.4) | 141 (45.2) |
| Diuretics | 65 (41.4) | 66 (42.6) | 131 (42.0) |
| Calcium Channel Blockers | 58 (36.9) | 67 (43.2) | 125 (40.1) |
| Beta Blocking Agents | 58 (36.9) | 59 (38.1) | 117 (37.5) |
| Analgesics | 55 (35.0) | 48 (31.0) | 103 (33.0) |
| Antibacterials For Systemic Use | 39 (24.8) | 36 (23.2) | 75 (24.0) |
| Antigout Agents | 34 (21.7) | 31 (20.0) | 65 (20.8) |
| Antiinflammatory And Antirheumatic Agents | 34 (21.7) | 25 (16.1) | 59 (18.9) |
| Antianemic Agents | 26 (16.6) | 24 (15.5) | 50 (16.0) |
| Urologicals | 23 (14.6) | 24 (15.5) | 47 (15.1) |
| Psycholeptics | 20 (12.7) | 23 (14.8) | 43 (13.8) |
Concomitant medication is any medication that the participant had been taking prior to enrollment and was expected to continue for some portion of the trial, as well as any medication other than the investigational product that was taken during the course of the trial. Medications are coded using WHO-DD version March 2016. Anatomical Therapeutic Chemical (ATC) classes and preferred terms are presented.